ConkbayirCYigitZHuralR, et al.Do restoring and maintaining sinus rhythm have a beneficial effect on secondary prevention of stroke in patients with atrial fibrillation? A pilot study. Angiology. 2019;70:916–20.
2.
PicciniJPStevensSRChangYet al; ROCKET AF Steering Committee and Investigators. Renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R(2)CHADS(2) index in the ROCKET AF (Rivaroxaban Once-daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (AnTicoagulation and Risk factors In Atrial fibrillation) study cohorts. Circulation. 2013;127:224–32.
3.
LinJT. Thromboembolic events in the cancer patient. J Women’s Health. 2003;12:541–551.
4.
ConnollySJEzekowitzMDYusufS, et al.Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139–51.
5.
LeeYJParkJKUhmJS, et al.Bleeding risk and major adverse events in patients with cancer on oral anticoagulation therapy. Int J Cardiol2016;203:372–8.
6.
YangPZhuDXuX, et al.Efficacy and safety of oral anticoagulants in atrial fibrillation patients with cancer—a network meta-analysis [published online ahead of print]. Heart Fail Rev. 2019. doi:10.1007/s10741-019-09844-8
7.
FranchiCAntoniazziSProiettiMNobiliAMannucciPM. Appropriateness of oral anticoagulant therapy prescription and its associated factors in hospitalized older people with atrial fibrillation. Br J Clin Pharmacol. 2018;84:2010–9.
8.
GatemanDTrojnarMEAgarwalG. Time in therapeutic range: warfarin anticoagulation for atrial fibrillation in a community-based practice. Can Fam Physician. 2017;63:e425–31.
